Other News To Note
• Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, said the European Committee for Medicinal Products for Human Use recommended approval of Xtandi (enzalutamide) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter